{Reference Type}: English Abstract
{Title}: [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
{Author}: Elovaara I;Atula S;Erälinna JP;Färkkilä M;Pirttilä T;Remes A;Ruutiainen J;Varis T; ; ;
{Journal}: Duodecim
{Volume}: 126
{Issue}: 2
{Year}: 2010
暂无{Abstract}: Treatment is initiated when the McDonald criteria for relapsing-remitting multiple sclerosis (RRMS) are fulfilled. High-risk patients with clinically isolated syndrome are followed using magnetic resonance imaging for one year after the first imaging. Interferon-beta or glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. MxA protein is measured 12 and 24 months after initiation of Interferon-beta to evaluate possible development of neutralizing antibodies. If MxA protein may not be detected repeatedly interferon-beta treatment is discontinued. If the disease is active in spite of treatment with first-line IMD, natalizumab may be considered as a second-line therapy. IMD is stopped when the transition to secondary progressive phase has occurred (or upon transition to secondary progressive phase).